Skip to content

Clinical Trial to Evaluate the Treatment of Atrial Fibrillation Using the Ablation Frontiers Cardiac Ablation System

Clinical Trial to Evaluate the Treatment of Atrial Fibrillation Using the Ablation Frontiers Cardiac Ablation System - The Atrial Fibrillation Ablation Pilot Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON31777
Enrollment
20
Registered
2006-07-31
Start date
2006-11-07
Completion date
Unknown
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation heart rhythm disorder

Interventions

Treatment of atrial fibrillation using the Ablation Frontiers Cardiac Ablation System.

Sponsors

Ablation Frontiers, Inc.
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: History of symptomatic permanent atrial fibrillation lasting greater than seven days but less than four years with at least one failed DC cardioversion within the previous two years.

Exclusion criteria

Exclusion criteria: Structural heart disease of clinical significance.

Design outcomes

Primary

MeasureTime frame
Acute - Use of AFI catheters to achieve procedure success. - Isolation of all accessible Pulmonary Veins - Elimination of CFAEs and high frequency intracardiac electrograms mapped and ablated with AFI catheters - Termination of AF upon leaving EP lab Chronic - Eighty percent reduction of sustained atrial fibrillation when evaluated for four consecutive days. - Off all rhythm control AADs at six months unless concomitant use for other cardiac disease.

Secondary

MeasureTime frame
- Improvement of left atrial size compared to baseline. - Improvement of LV ejection fraction compared to baseline. - Improved Symptom Severity Score compared to baseline. - Improvement in the QoL.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)